GlaxoSmithKline hope to offer first inoculations in 2022
In the UK, GlaxoSmithKline is beginning a trial of a new combined Covid vaccine involving 4,000 people.
The British drugs giant has teamed up with South Korean pharmaceutical firm SK Bioscience.
GSK is hoping to offer vaccinations in the first half of 2022, if results are positive.
#News for #investors and #media: We’ve just announced the start of a Phase 3 clinical trial for an adjuvanted #COVID19 vaccine candidate we’re co-developing with SK bioscience. Find out more about our response to COVID-19: https://t.co/xbd8I3Mmqh pic.twitter.com/8plipJ8mov
— GSK (@GSK) August 31, 2021
Newbridge Concern Worldwide Worker Documents Ongoing Suffering in Sudan
